ஜர்னல் ஆஃப் மெட்டபாலிக் சிண்ட்ரோம்

CXCR4-stem cell therapy in old myocardial infarction

Abstract

Jose Luis Aceves

For cell therapy on myocardial infarction, many kinds of cells have been studied. In our experience since 2001, the implant of mesenchyme stem cells CD34+ obtained from peripheral blood showed inconsistent improvement in the contractile function of infarcted myocardial tissue, but better survival in long term. For improved cell therapy, in 2014 we characterized the kind of cells that were mobilized to peripheral blood in patients with acute myocardial infarction, which were identified as a response of bone marrow to myocardial insult. In 2015, we began a clinical trial with CXCR4-stem cells and specific cell markers in patients with old myocardial infarction and reduced LVFE. Cells with specific markers were separated with immune-magnetic auto MACS Pro Separator machine and implanted on infarcted myocardial tissue guided by epicardial ultrasound.